Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11911610 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TSHRTDP1 | |
| SCHEMBL12442469 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TSHRTDP1 | |
| SCHEMBL12220181 | 0.77 | — | — | |
| SCHEMBL11911971 | 0.77 | — | — | |
| SCHEMBL15966007 | 0.77 | — | — | |
| SCHEMBL1696744 | 0.74 | ALDH1A1 (0.30) | ALDH1A1TSHRTDP1 | |
| SCHEMBL16326345 | 0.72 | — | — | |
| SCHEMBL12220678 | 0.72 | TSHR (0.41) | ALDH1A1TSHRTDP1 | |
| SCHEMBL13079167 | 0.72 | — | — | |
| SCHEMBL16054614 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450522-B2 | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8030354-B2 | 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20110190330-A1 | SPIROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | GPR119, GPR65, GPR55 | ALDH1A1 1149/4885TSHR 740/4885TDP1 4768/4885 |
| US-20110190330-A1 | SPIROCYCLIC GPR40 MODULATORS | GPR119, GPR55, GPR65 | ALDH1A1 1173/4885TSHR 1166/4885TDP1 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.